Sone Capital Management LLC Takes Position in Stryker Corporation $SYK

Sone Capital Management LLC acquired a new position in Stryker Corporation (NYSE:SYK) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 22,151 shares of the medical technology company’s stock, valued at approximately $6,974,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Stryker in the fourth quarter valued at $1,822,272,000. Auto Owners Insurance Co raised its position in Stryker by 35,047.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock valued at $1,024,444,000 after buying an additional 2,906,448 shares during the period. Flossbach Von Storch SE purchased a new stake in Stryker in the 2nd quarter worth about $464,506,000. Wellington Management Group LLP boosted its position in Stryker by 22.6% during the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock worth $2,282,192,000 after acquiring an additional 1,198,665 shares during the period. Finally, Corient Private Wealth LLC grew its stake in Stryker by 104.4% during the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after acquiring an additional 1,146,998 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Trading Down 0.5%

Shares of NYSE SYK opened at $327.80 on Tuesday. The business has a 50 day simple moving average of $327.39 and a 200 day simple moving average of $332.16. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.86. The stock has a market cap of $125.73 billion, a price-to-earnings ratio of 33.97, a PEG ratio of 2.10 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter last year, the firm earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts predict that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the transaction, the director directly owned 2,251,375 shares in the company, valued at $765,692,637.50. This trade represents a 2.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Debra King sold 826 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares of the company’s stock, valued at $2,088,423. This represents a 11.74% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 355,370 shares of company stock valued at $119,447,201. Insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

SYK has been the subject of several research reports. Truist Financial raised their price target on shares of Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a report on Friday, July 31st. Sanford C. Bernstein set a $410.00 price objective on shares of Stryker in a research note on Friday, May 1st. JPMorgan Chase & Co. cut their target price on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Royal Bank Of Canada decreased their target price on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. Finally, Robert W. Baird set a $385.00 price target on shares of Stryker in a research note on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.